De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This study is a prospective, randomized, open-label, non-inferiority Phase III clinical trial, planning to enroll 2,934 patients, with a 1:1 allocation to either the conventional endocrine therapy group or the de-escalation therapy group. The aim is to evaluate the safety and efficacy of 2-3 years of de-escalated endocrine therapy in patients with T1N0M0 potentially low-risk breast cancer, respectively.
Epistemonikos ID: 0c8f89f9660efe03e3c076dc742a65a324c4cf86
First added on: Sep 05, 2025